GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Gain Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.25−0.01 (-0.79%)
Close on Oct 19, 2026
- Market cap
- $53.60M
- P/E (TTM)
- –
- Dividend yield
- –
Gain Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Gain Therapeutics | Industry median |
|---|---|---|
| Market Cap | $54.55M | $166.30M |
| Enterprise Value | $41.81M | $88.19M |
| PB Ratio | 4.83 | 2.03 |
| P/TBV Ratio | 4.83 | 2.29 |
Income (trailing twelve months)
| Measure | Gain Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$19.29M | -$21.40M |
| Pretax Income | -$19.20M | -$14.34M |
| Net Income | -$20.11M | -$22.46M |
| EBITDA | -$19.19M | -$16.91M |
| EPS (Diluted) | -$0.51 | -$0.83 |
Returns
| Measure | Gain Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -268.3% | -53.2% |
| Return on Assets (ROA) | -159.2% | -40.9% |
| Return on Capital Employed (ROCE) | -160.9% | -38.1% |
Balance sheet
| Measure | Gain Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $13.08M | $61.43M |
| Total Debt | $343.69K | $118.52M |
| Net Cash (Debt) | $12.74M | $15.35M |
| Net Cash Per Share | $0.29 | $0.66 |
| Equity (Book Value) | $11.29M | $49.09M |
| Book Value Per Share | $0.26 | $1.37 |
| Tangible Book Value | $11.29M | $23.52M |
| Working Capital | $11.54M | $76.81M |
Financial position
| Measure | Gain Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.36 | 3.34 |
| Quick Ratio | 3.81 | 2.44 |
| Debt / Equity | 0.03 | 0.52 |
Cash flow (trailing twelve months)
| Measure | Gain Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$18.95M | -$12.35M |
Efficiency
| Measure | Gain Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.01M | -$703.34K |
| Employee Count | 20 | 74 |
Dividends and yields
| Measure | Gain Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -36.9% | -23.3% |
Shares
| Measure | Gain Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 43,643,600 | 58,127,000 |
| Shares Change (YoY) | 39.4% | 10.9% |
| Shares Change (QoQ) | 2.01% | 0.54% |
| Float | 42,364,000 | 49,136,700 |
| Shares Held by Insiders | 2.93% | 11.6% |
| Shares Held by Institutions | 21.1% | 59.4% |
Taxes
| Measure | Gain Therapeutics | Industry median |
|---|---|---|
| Income Tax | $906.54K | $79.87K |
Scores
| Measure | Gain Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -5.44 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Gain Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.